Millennium & ILEX Partners, the joint venture between MillenniumPharmaceuticals and ILEX Oncology, has been granted authorization by the European Medicines Evaluation Agency to market MabCampath (alemtuzumab), its humanized monoclonal antibody for patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating drugs and have failed fludarabine therapy. MabCampath will be marketed in Europe by Schering AG.
The antibody was launched in the USA in May, as Campath, by Schering's US affiliate Berlex Laboratories (Marketletter May 21). M&I has said it is now starting a post-approval clinical trial of MabCampath versus chlorambucil, the standard first-line treatment for B-CLL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze